Abstract
A minophylline has been observed to decrease cerebral blood flow in normotensive control subjects, 1 patients with heart failure, 2 and patients with hypertension associated with severe headache. 3 At least in the latter group of patients, the cerebrospinal fluid pressure decrease concurrently with the reduction in cerebral blood flow. Recently a xanthine compound (Parephyllin) (Soluphylline or R-3588) ∗ ∗ Supplied through the courtesy of Riker Laboratories, Inc. has been introduced which has gained widespread use in France 4,5 under the trade name Soluphylline. It produces less gastric irritation than aminophylline and, therefore, it can be given in large doses orally. In addition, it is not irritating by the intramuscular route of administration. Because of these qualities, it seemed worthwhile to study the pharmacodynamics of this drug and to compare it with aminophylline. The current study is concerned with an evaluation of the cerebrovascular hemodynamic response to this compound (Parephyllin).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
